{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:10:16Z","timestamp":1791670216744,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PI-0131\/2020"],"award-info":[{"award-number":["PI-0131\/2020"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","award":["UMA20-FEDERJA-074"],"award-info":[{"award-number":["UMA20-FEDERJA-074"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020230","name":"Government of Andalusia Ministry of Economic Transformation Industry Knowledge and Universities","doi-asserted-by":"publisher","award":["ProyExcel_01009"],"award-info":[{"award-number":["ProyExcel_01009"]}],"id":[{"id":"10.13039\/100020230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009473","name":"University of Malaga","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011772","name":"Novartis Pharmaceuticals","doi-asserted-by":"publisher","award":["LCZ696-2017"],"award-info":[{"award-number":["LCZ696-2017"]}],"id":[{"id":"10.13039\/501100011772","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023731","name":"Regional Government of Andalusia Ministry of Health and Consumer Affairs","doi-asserted-by":"publisher","award":["RH-0095-2020"],"award-info":[{"award-number":["RH-0095-2020"]}],"id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023731","name":"Regional Government of Andalusia Ministry of Health and Consumer Affairs","doi-asserted-by":"publisher","award":["PI-0131\/2020"],"award-info":[{"award-number":["PI-0131\/2020"]}],"id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016970","name":"Consejer\u00eda de Econom\u00eda, Conocimiento, Empresas y Universidad, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016970","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["CM23\/00125"],"award-info":[{"award-number":["CM23\/00125"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI23\/00293"],"award-info":[{"award-number":["PI23\/00293"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010566","name":"Consejer\u00eda de Salud y Familias, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.biopha.2025.117874","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T01:08:23Z","timestamp":1738199303000},"page":"117874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effects of sacubitril\/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: An integrated study of molecular biomarkers and imaging techniques"],"prefix":"10.1016","volume":"183","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6212-9959","authenticated-orcid":false,"given":"Ainhoa","family":"Robles-Mezcua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Januzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Pav\u00f3n-Mor\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-6264","authenticated-orcid":false,"given":"Jorge","family":"Rodr\u00edguez-Capit\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"L\u00f3pez-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Cruzado-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5033-4880","authenticated-orcid":false,"given":"Mar\u00eda","family":"Robles-Mezcua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0898-8212","authenticated-orcid":false,"given":"Mario","family":"Guti\u00e9rrez-Bedmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Couto-Mall\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9717-6915","authenticated-orcid":false,"given":"Eloy C.","family":"Rueda-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Barreiro-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"G\u00f3mez-Doblas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel F.","family":"Jim\u00e9nez-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Garc\u00eda-Pinilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.117874_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib2","doi-asserted-by":"crossref","first-page":"E139","DOI":"10.1161\/CIR.0000000000000757","article-title":"D.G. Heard, Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.117874_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.carpath.2011.11.007","article-title":"The pathophysiology of heart failure","volume":"21","author":"Kemp","year":"2012","journal-title":"Cardiovasc. Pathol."},{"key":"10.1016\/j.biopha.2025.117874_bib4","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.jacc.2011.01.009","article-title":"Ventricular remodeling: Fundamental to the progression (and regression) of heart failure","volume":"57","author":"Udelson","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib5","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/ejhf.949","article-title":"Barcelona Bio-HF Calculator Version 2.0: incorporation of angiotensin II receptor blocker neprilysin inhibitor (ARNI) and risk for heart failure hospitalization","volume":"20","author":"Lup\u00f3n","year":"2018","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib6","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1161\/CIRCULATIONAHA.105.561423","article-title":"Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients","volume":"112","author":"Solomon","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.117874_bib7","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.hrthm.2014.11.014","article-title":"The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: Results of the REVERSE study","volume":"12","author":"Gold","year":"2015","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.biopha.2025.117874_bib8","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin Inhibition versus Enalapril in Heart Failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117874_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.117874_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.754499","article-title":"Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review","volume":"8","author":"Pascual-Figal","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.biopha.2025.117874_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of Sacubitril\/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF","volume":"73","author":"Zile","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib13","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jacc.2017.09.031","article-title":"Soluble ST2 for Prognosis and Monitoring in Heart Failure: The New Gold Standard?","volume":"70","author":"Bay\u00e9s-Gen\u00eds","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib14","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005582","article-title":"ST2 in Heart Failure","volume":"11","author":"Bay\u00e9s-Genis","year":"2018","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib15","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10741-019-09807-z","article-title":"Biomarkers in heart failure: the past, current and future","volume":"24","author":"Sarhene","year":"2019","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.biopha.2025.117874_bib16","doi-asserted-by":"crossref","first-page":"70B","DOI":"10.1016\/j.amjcard.2015.01.044","article-title":"ST2 testing for chronic heart failure therapy monitoring: The international ST2 consensus panel","volume":"115","author":"Januzzi","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.hfc.2017.08.005","article-title":"Soluble ST2 in Heart Failure","volume":"14","author":"McCarthy","year":"2018","journal-title":"Heart Fail Clin."},{"key":"10.1016\/j.biopha.2025.117874_bib18","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.jacc.2018.08.2165","article-title":"sST2 Predicts Outcome in Chronic Heart Failure Beyond NT\u2212proBNP and High-Sensitivity Troponin T","volume":"72","author":"Emdin","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib19","first-page":"468","article-title":"Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide","volume":"10","author":"Filipiak","year":"2023","journal-title":"J. Cardiovasc. Dev. Dis. 2023"},{"key":"10.1016\/j.biopha.2025.117874_bib20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.recesp.2023.02.010","article-title":"ST2 circulante: un pat\u00f3geno, m\u00e1s que un biomarcador","volume":"76","author":"Pascual-Figal","year":"2023","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib21","article-title":"Soluble ST2 levels are related to replacement myocardial fibrosis in severe aortic stenosis","author":"Arrieta","year":"2022","journal-title":"Rev. Esp. Cardiol. (Engl. Ed. ) ("},{"issue":"2016","key":"10.1016\/j.biopha.2025.117874_bib22","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2025.117874_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur. Heart J. Cardiovasc Imaging"},{"key":"10.1016\/j.biopha.2025.117874_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9149(02)02381-0","article-title":"Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy","volume":"90","author":"Grothues","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib25","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJM200011163432003","article-title":"The Use of Contrast-Enhanced Magnetic Resonance Imaging to Identify Reversible Myocardial Dysfunction","volume":"343","author":"Kim","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117874_bib26","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/01.CIR.64.6.1227","article-title":"Comparative reproducibility and validity of systems for assessing cardiovascular functional class: advantages of a new specific activity scale","volume":"64","author":"Goldman","year":"1981","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2025.117874_bib27","article-title":"Sacubitril\/valsartan in heart failure: efficacy and safety in and outside clinical trials","volume":"9","author":"Abdin","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1701","article-title":"Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T","volume":"22","author":"Aimo","year":"2020","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib29","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117874_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s40268-023-00438-2","article-title":"Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril\/Valsartan: A Hint to Different Therapeutic Pathways","volume":"23","author":"Mapelli","year":"2023","journal-title":"Drugs R. D."},{"key":"10.1016\/j.biopha.2025.117874_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2018.08.2165","article-title":"sST2 Predicts Outcome in Chronic Heart Failure Beyond NT\u2212proBNP and High-Sensitivity Troponin T","volume":"72","author":"Emdin","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib32","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004446","article-title":"Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart","volume":"11","author":"O\u2019Meara","year":"2018","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2010.07.014","article-title":"Establishment of reference intervals for soluble ST2 from a United States population","volume":"411","author":"Lu","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.biopha.2025.117874_bib34","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: A randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2025.117874_bib35","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in n-terminal pro-b-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA - J. Am. Med. Assoc."},{"key":"10.1016\/j.biopha.2025.117874_bib36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013Neprilysin Inhibition in Acute Decompensated Heart Failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.117874_bib37","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.117874_bib38","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure","volume":"68","author":"Zile","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib39","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: Meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2025.117874_bib40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"Von Lueder","year":"2015","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib41","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/ejhf.474","article-title":"LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice","volume":"18","author":"Suematsu","year":"2016","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jchf.2018.10.014","article-title":"NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF","volume":"7","author":"Daubert","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib43","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008410","article-title":"Association between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure with Reduced Ejection Fraction","volume":"14","author":"Murphy","year":"2021","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jjcc.2021.03.014","article-title":"Serum NT-proBNP levels and histopathological myocardial fibrosis in autopsied cases from a Japanese community: The Hisayama Study","volume":"78","author":"Sasaki","year":"2021","journal-title":"J. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib45","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011146","article-title":"Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction","author":"Azzo","year":"2024","journal-title":"Circ. Heart Fail"},{"key":"10.1016\/j.biopha.2025.117874_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2017.10.044","article-title":"Association of Elevated NT-proBNP With Myocardial Fibrosis in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"70","author":"Liu","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2025.117874_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.biopha.2025.117874_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12093136","article-title":"sST2 and Heart Failure\u2014Clinical Utility and Prognosis","volume":"12","author":"Dudek","year":"2023","journal-title":"J. Clin. Med"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500068X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222500068X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:47:07Z","timestamp":1777574827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222500068X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":48,"alternative-id":["S075333222500068X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117874","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of sacubitril\/valsartan on cardiac remodeling in heart failure with reduced ejection fraction: An integrated study of molecular biomarkers and imaging techniques","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117874"}}